Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants, 50-85 years of age
Participants with prodromal Alzheimer's disease who are not receiving memantine or cholinesterase inhibitors
Has a study partner who in the investigator's judgement has frequent and sufficient contact with the participant as to be able to provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at clinic visits which require partner input for scale completion
Has had sufficient education or work experience to exclude mental retardation
Study partner has noticed a recent gradual decrease in participant's memory (over the last 12 months), which the participant may or may not be aware of
Screening Mini Mental State Exam (MMSE) score of 24 or above
Able and willing to travel to PET imaging center and complete the planned scanning sessions
Past and planned exposure to ionizing radiation not exceeding safe and permissible levels
You may not be if
Other prior or current neurologic or medical disorder which may currently or during the course of the study impair cognition or psychiatric functioning
A history of stroke
A documented history of transient ischemic attack within the last 12 months
History of schizophrenia, schizoaffective or bipolar disorder
Currently meets criteria for major depression
Within the last 2 years, unstable or clinical significant cardiovascular disease (myocardial infarction, angina pectoris)
Inclusion in a research and/or medical protocol involving PET ligands or other radioactive agents within 12 months
Present or planned participation in a research and/or medical protocol involving PET ligands or radioactive agents other than study WN25203
Have planned or are planning to have exposure to ionizing radiation that in combination with the planned administration with study amyloid PET ligand would result in a cumulative exposure that exceeds local recommended exposure limits
Clareo Health | A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
